VSIG4 (US10927183B2 Biosimilar) Recombinant Monoclonal Antibody
-
貨號:CSB-RA896869MB1HU
-
規(guī)格:¥83486
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:VSIG4 (US10927183B2 Biosimilar Antibody) 重組單克隆抗體是一種針對人VSIG4蛋白,其別名為補體受體免疫球蛋白超家族抗體(CRIg antibody)、免疫球蛋白超家族蛋白抗體、Z39Ig抗體等,屬于V型免疫球蛋白結(jié)構(gòu)域蛋白家族成員。該抗體以重組人VSIG4蛋白制備,具有高度特異性,僅與人源VSIG4發(fā)生反應,種屬反應性明確限定為人類,為精準靶向研究奠定基礎(chǔ)。 基于VSIG4作為免疫調(diào)節(jié)關(guān)鍵分子的特性,相關(guān)藥物展現(xiàn)出潛在治療價值。VSIG4在巨噬細胞表面高表達,通過調(diào)控補體系統(tǒng)激活及T細胞免疫應答參與炎癥反應和免疫耐受過程。目前研究聚焦于自身免疫性疾?。ㄈ珙愶L濕關(guān)節(jié)炎、系統(tǒng)性紅斑狼瘡)和腫瘤免疫治療領(lǐng)域,初步結(jié)果顯示針對VSIG4類似物可通過阻斷其介導的免疫抑制信號,增強抗腫瘤免疫應答或減輕過度炎癥損傷。此外,其特性意味著在保證療效的同時,可能降低治療成本,提升藥物可及性。 VSIG4重組單克隆抗體是探索免疫調(diào)控機制的重要工具。由于其嚴格的人源種屬反應性,適用于人細胞系、組織樣本及人源化動物模型的實驗研究。研究者可利用該抗體進行VSIG4蛋白的表達定位、相互作用蛋白篩選及功能驗證,例如通過分析巨噬細胞亞群的VSIG4表達水平,或通過免疫共沉淀探究其與補體成分C3b的結(jié)合機制。此外,在藥物開發(fā)前期,該抗體可用于靶點驗證和藥效評估,為臨床前研究提供可靠的實驗數(shù)據(jù)支持。 綜上,VSIG4重組單克隆抗體兼具臨床轉(zhuǎn)化潛力與科研應用價值,其高度特異性和人源靶向性為免疫相關(guān)疾病的機制研究及治療策略開發(fā)提供了有力工具,有望在免疫治療領(lǐng)域發(fā)揮重要作用。
-
Uniprot No.:
-
基因名:
-
別名:Complement receptor of the immunoglobulin superfamily antibody; CRIg antibody; Ig superfamily protein antibody; Protein Z39Ig antibody; UNQ317/PRO362 antibody; V set and immunoglobulin domain containing 4 antibody; V-set and immunoglobulin domain-containing protein 4 antibody; VSIG4 antibody; VSIG4_HUMAN antibody; Z39IG antibody
-
反應種屬:Human
-
免疫原:Recombinant Human VSIG4 protein
-
免疫原種屬:Homo sapiens (Human)
-
標記方式:Non-conjugated
-
克隆類型:Monoclonal
-
濃度:It differs from different batches. Please contact us to confirm it.
-
保存緩沖液:0.01M PBS,pH7.4
-
產(chǎn)品提供形式:Liquid
-
應用說明:Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method. -
儲存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期:In stock
-
用途:It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
相關(guān)產(chǎn)品
靶點詳情
-
功能:Phagocytic receptor, strong negative regulator of T-cell proliferation and IL2 production. Potent inhibitor of the alternative complement pathway convertases.
-
基因功能參考文獻:
- Soluble VSIG4 levels are associated with the progression and recurrence of ovarian cancer, indicating that soluble VSIG4 may be used as a potential biomarker for predicting tumor prognosis. PMID: 28498255
- VSIG4 signaling provides an anti-immune evasion mechanism that prevents the outgrowth of intracellular bacteria in macrophages PMID: 27440002
- The VSIG4 upregulation by LMP1 was regulated at the transcriptional level via the NF-kB signaling axis. PMID: 28859984
- VSIG4 expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
- we concluded that let-7g-5p inhibits epithelial-mesenchymal transition (EMT) consistent with reduction of glioma stem cell (GSC) phenotypes by targeting VSIG4 in glioblastoma. PMID: 27634309
- Data indicate that rotein kinase calpha (PKCalpha) plays a role in downregulating complement receptor Ig (CRIg coded by V-set and Ig domain-containing protein 4 VSIG4) expression. PMID: 25687755
- complement receptor of the immunoglobulin superfamily-L-factor H protects glomerular mesangial cells from complement-mediated injury and proliferative lesions PMID: 25114177
- we identified VSIG4 as a potential diagnostic marker of severe preeclampsia. The determination of this gene may improve the prognostic assessment of severe preeclampsia. PMID: 24349325
- Data indicate that massive V-set and Ig domain-containing 4 VSIG4(+) cell infiltration throughout the non-small-cell lung cancer samples. PMID: 24862966
- we showed that a complement receptor of the Ig superfamily (CRIg, also known as Z39Ig), a receptor for complement fragments (C3b and iC3b), was expressed on a subset of intestinal macrophages in murine and human large intestine PMID: 21768202
- These results suggest that T cells can opposite T cell hyporesponsiveness through dampening Z39Ig inhibitory signals from macrophages and thus maintain their anti-viral function in chronic hepatitis B. PMID: 20399148
- hVSIG4 recombinant adenovirus-transfected DCs suppress T cell proliferation, cytokine production and activation marker expression with PMID: 19914289
- Results report the identification and characterization of a Complement Receptor of the Immunoglobulin superfamily, CRIg, that binds complement fragments C3b and iC3b. PMID: 16530040
- These data indicate that the macrophage Z39Ig is involved in the pathogenesis of inflammatory diseases through chemokine induction, which will promote the migration of inflammatory cells into the lesion area, and MMP-9 induction. PMID: 16882875
- The specific expression of VSIG4 on resting macrophages suggests that VSIG4 may be important for the maintenance of T cell unresponsiveness in healthy tissues. PMID: 17016562
- CRIg is not only a phagocytic receptor, but also a potent inhibitor of the alternative pathway convertases PMID: 17051150
顯示更多
收起更多
-
亞細胞定位:Membrane; Single-pass type I membrane protein.
-
組織特異性:Abundantly expressed in several fetal tissues. In adult tissues, highest expression in lung and placenta. Expressed in resting macrophages.
-
數(shù)據(jù)庫鏈接:
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-















